RT Journal Article
SR Electronic
T1 Age significantly influences the sensitivity of SARS-CoV-2 rapid antibody assays
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.28.21250675
DO 10.1101/2021.01.28.21250675
A1 Irwin, Natalie
A1 Murray, Lyle
A1 Ozynski, Benjamin
A1 Richards, Guy A
A1 Paget, Graham
A1 Venturas, Jacqueline
A1 Kalla, Ismail
A1 Diana, Nina
A1 Mahomed, Adam
A1 Zamparini, Jarrod
YR 2021
UL http://medrxiv.org/content/early/2021/02/01/2021.01.28.21250675.abstract
AB BACKGROUND Point of care serological assays are a promising tool in COVID-19 diagnostics but do have limitations. This study evaluated the sensitivity of five rapid antibody assays and explored factors influencing their sensitivity to detect SARS-CoV-2-specific IgG and IgM antibodies.METHODS Finger-prick blood samples from 102 participants, within two to six weeks of PCR-confirmed COVID-19 diagnosis, were tested for IgG and IgM on five rapid serological assays. The assay sensitivities were compared, and patient factors evaluated in order to investigate potential associations with assay sensitivity.RESULTS Sensitivity ranged from 36% to 69% for IgG and 13% to 67% for IgM. Age was the only factor significantly influencing the likelihood of a detectable IgG or IgM response. Individuals aged 40 years and older had an increased likelihood of a detectable IgG or IgM antibody response by rapid antibody assay.CONCLUSION Rapid serological assays demonstrate significant variability when used in a real-world clinical context. There may be limitations in their use for COVID-19 diagnosis amongst the young.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFirst Medical Company, Cape Town; SMD Technologies, Johannesburg and Altis Biologics, Pretoria donated test assays for use in this study but had no role in the study design, data collection, data analysis and/or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of the Witwatersrand Human Research Ethics Committee (Medical) Certificate: M200697All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available from Dr Natalie Irwin and/or Dr Jarrod Zamparini